Globe Newswire06.20.19
CHF Solutions has hired Nestor Jaramillo Jr. as its new chief commercial officer.
“Nestor has been a key player in medical device commercialization for more than 20 years and has led commercial organizations in both startup and multinational companies,” said John Erb, CEO of CHF Solutions. “With Nestor in place, we look forward to enhancing our sales and marketing execution which will drive our revenue growth.”
Prior to joining CHF Solutions, Jaramillo was president and CEO of Innerspace Neuro Solutions Inc., a Tustin, Calif.-based commercial-stage medical technology company that developed, manufactured and distributed an intracranial pressure monitoring system. He also worked in a variety of capacities at startup Transoma Medical, St. Jude Medical Inc., and at Medtronic plc. In addition, he also spent seven years as a managing director of healthcare investment banking at both Cherry Tree & Associates and Craig-Hallum Capital, both in Minneapolis.
Jaramillo earned an engineering degree from the University of North Dakota and a master's degree in business administration from the University of St. Thomas in Minneapolis.
“I’m excited to work with an organization that is providing the medical community a unique approach to fluid management with the goal of improving clinical outcomes for patients, whether in the hospital or outpatient clinic setting,” said Jaramillo. “CHF Solutions is continually seeking new applications and venues for the Aquadex FlexFlow ultrafiltration system and I look forward to working with the team to further expand our market presence and provide this life-changing therapy to the many patients who urgently need it.”
CHF Solutions Inc. is a medical device company focused on commercializing the Aquadex FlexFlow system for aquapheresis therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended (longer than eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.
“Nestor has been a key player in medical device commercialization for more than 20 years and has led commercial organizations in both startup and multinational companies,” said John Erb, CEO of CHF Solutions. “With Nestor in place, we look forward to enhancing our sales and marketing execution which will drive our revenue growth.”
Prior to joining CHF Solutions, Jaramillo was president and CEO of Innerspace Neuro Solutions Inc., a Tustin, Calif.-based commercial-stage medical technology company that developed, manufactured and distributed an intracranial pressure monitoring system. He also worked in a variety of capacities at startup Transoma Medical, St. Jude Medical Inc., and at Medtronic plc. In addition, he also spent seven years as a managing director of healthcare investment banking at both Cherry Tree & Associates and Craig-Hallum Capital, both in Minneapolis.
Jaramillo earned an engineering degree from the University of North Dakota and a master's degree in business administration from the University of St. Thomas in Minneapolis.
“I’m excited to work with an organization that is providing the medical community a unique approach to fluid management with the goal of improving clinical outcomes for patients, whether in the hospital or outpatient clinic setting,” said Jaramillo. “CHF Solutions is continually seeking new applications and venues for the Aquadex FlexFlow ultrafiltration system and I look forward to working with the team to further expand our market presence and provide this life-changing therapy to the many patients who urgently need it.”
CHF Solutions Inc. is a medical device company focused on commercializing the Aquadex FlexFlow system for aquapheresis therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended (longer than eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.
